Finally, determination of the contribution of brain FXR activation to the clinical actions of synthetic FXR ligands, several of which being currently in development for the treatment of metabolic diseases, such as non-alcoholic fatty liver disease, will be of interest. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.